| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | trifluoperazine | CTRPv2 | pan-cancer | AAC | -0.037 | 0.3 |
| mRNA | Vandetanib | CCLE | pan-cancer | AAC | 0.045 | 0.3 |
| mRNA | Vandetanib | FIMM | pan-cancer | AAC | -0.17 | 0.3 |
| mRNA | EKB-569 | GDSC1000 | pan-cancer | AAC | 0.032 | 0.3 |
| mRNA | KU-55933 | GDSC1000 | pan-cancer | AAC | 0.034 | 0.3 |
| mRNA | LE-135 | CTRPv2 | pan-cancer | AAC | 0.035 | 0.3 |
| mRNA | MLN2238 | CTRPv2 | pan-cancer | AAC | 0.033 | 0.3 |
| mRNA | BRD-K97651142 | CTRPv2 | pan-cancer | AAC | -0.035 | 0.4 |
| mRNA | azacitidine | CTRPv2 | pan-cancer | AAC | -0.035 | 0.4 |
| mRNA | MS-275 | gCSI | pan-cancer | AAC | -0.049 | 0.4 |